Titration and discontinuation of semaglutide for weight management in commercially insured US adults
Obesity · 2025-07 · 33 (7) · 1243-1248
DOI: 10.1002/oby.24315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity, online erschienen am 04.06.2025. Verfasst von Yunwen Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Objective
The objective of this study is to examine real‐world dose titration patterns of semaglutide for weight management (Wegovy, Novo Nordisk A/S) in US adults and identify characteristics associated with early discontinuation.
Methods
We identified 15,811 commercially insured adults who started semaglutide for weight management (administrated through single‐dose prefilled pens) between June 2021 and December 2023. We depicted dose‐titration patterns over 5 months and identified factors associated with discontinuation using multivariable Cox regression. Sensitivity analyses examined patterns after supply shortage resolution (after October 2023).
Results
Most semaglutide users deviated from the recommended monthly dose‐escalation schedule within the first 5 months. By the fifth month, nearly one‐half (46%) had discontinued the treatment, with similar rates (48%) among those initiating after supply stabilization. Discontinuation was strongly associated with copayment amount, with rates increased from 41% in the lowest quintile ($1–$54 per month) to 51% in the highest quintile ($161–$1460 per month). Higher discontinuation rates were also associated with lower household income and education level.
Conclusions
The deviations from the recommended dose‐escalation schedule and high discontinuation rate among real‐world semaglutide users indicate important challenges in the delivery of evidence‐based care. Policy interventions that reduce financial barriers to the persistence of semaglutide are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
- Division of Nephrology, Department of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden.
- Departments of Nephrology and Population Health Sciences, Geisinger, Danville, Pennsylvania, USA.
- Division of Nephrology, Department of Internal Medicine, Tufts Medical Center, Boston, Massachusetts, USA.
- Center for Population Health and Health Services Research, Department of Foundations of Medicine, New York University Grossman Long Island School of Medicine, Mineola, New York, USA.
ORCID-Profile: Yunwen Xu, Alexander R Chang
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Xu, Y., Carrero, J. J., Chang, A. R., Inker, L. A., Zhang, D., Mukhopadhyay, A., Blecker, S. B., Horwitz, L. I., Grams, M. E., & Shin, J. I. (2025). Titration and discontinuation of semaglutide for weight management in commercially insured US adults. Obesity, 33(7), 1243-1248. https://doi.org/10.1002/oby.24315
Vancouver
Xu Y, Carrero JJ, Chang AR, Inker LA, Zhang D, Mukhopadhyay A, et al. Titration and discontinuation of semaglutide for weight management in commercially insured US adults. Obesity. 2025;33(7):1243-1248. doi:10.1002/oby.24315
BibTeX
@article{Xu2025,
author = {Xu, Yunwen and Carrero, Juan J and Chang, Alexander R and Inker, Lesley A and Zhang, Donglan and Mukhopadhyay, Amrita and Blecker, Saul B and Horwitz, Leora I and Grams, Morgan E and Shin, Jung-Im},
title = {Titration and discontinuation of semaglutide for weight management in commercially insured US adults},
journal = {Obesity},
year = {2025},
volume = {33},
number = {7},
pages = {1243--1248},
doi = {10.1002/oby.24315}
}
EUVIMED